Emcure Pharmaceuticals to launch oral COVID-19 drug in a week’s time in India

Emcure Pharmaceuticals announced that it has received an Emergency Use Authorisation (EUA) approval from the Drug Controller General of India (DCGI) for launching Molnupiravir to treat mild COVID-19. The company plans to launch the oral drug under the brand name Lizuvira in the Indian market, the company said in a statement.

As the need for such a drug is imminent in the face of emerging challenges in COVID- 19 treatment, the company will endeavour to deliver Lizuvira in a week’s time. A toll-free helpline will be dedicated to help the doctors and patients access the product.

Earlier this year, Emcure Pharma had entered into a licensing agreement with Merck Sharpe Dohme (MSD) to manufacture and supply Molnupiravir to India and over 100 low- and middle-income countries (LMICs).